It looks like your are using Internet Explorer.
Unfortunately, Internet Explorer is an outdated browser and we do not currently support it fully. You are seeing a limited view of the meeting details below.
To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.
Combo DTx-drug: Pharma Opportunities
DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?
This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss:
- How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?
- When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?
- Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs?
- What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos?
- What does the promotion of these combos look like?
An invite invite link has been sent to you if you do not already have a HealthXL account.
An invite link will be sent to your inbox.
Combo DTx-drug: Pharma Opportunities
Join this HealthXL Event today:
Participate in this Digital Health Sprint in order to:
- Deep dive into a topic over 2 focused sessions.
- Engage with a small group of 10 global thought-leaders throughout.
- This sprint is outcome-focused: HealthXL and participants create exclusive outputs.
- Grow your network with our break out sessions.
You actively participate in this discussion. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.
Don't miss your opportunity to connect with senior leaders to shape the future of digital health. Because only if you are prepared now can you lead the future.
DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?
This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss:
- How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?
- When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?
- Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs?
- What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos?
- What does the promotion of these combos look like?
Participants
Participants
Smit Patel
Director of Digital Medicine at DiMe
Randy Horton
Chief Solutions Officer, Orthogonal
Tahir Hussain
European BD Director - Digital Therapeutics (DTx), Biofourmis
Anish Shindore
Founder & Managing Partner, GSD Health
Uma Makhija Verma
Senior Director, Business Development, Biogen
Tim Jurgens
Co-Founder & General Manager en SeedLink SL
Ricardo C. Berrios
Executive Founder, Adhera Health Inc
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Emily Kunka
Digital Transformation Project Lead, UCB
Chris Wasden
Chief Strategy Officer, Twill
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Jaydev Thakkar
Chief Operating Officer at Biofourmis
Maxime Champain
Lead, BDH External Innovation & Alliances, Search & Evaluation, Biogen
Steve Gowers
Head of Drug Delivery and Digital Health, TTP
Simon Bock
Market Access Manager, Tiefenbacher Group
Up to 12
Combo DTx-drug: Pharma Opportunities
DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?
This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss:
- How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?
- When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?
- Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs?
- What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos?
- What does the promotion of these combos look like?
HealthXL Roundtables
HealthXL community meetings connect senior leaders from around the world.
Our virtual Roundtables are small, participant-led discussions where the HealthXL community discuss digital health challenges and offer solutions.
HealthXL community members lead discussion on a defined topic among a maximum of 12 participants. There is no audience and no recordings, just an interactive space to reflect and share learnings.
At 60-minutes long, roundtables are long enough for meaningful discussion among peers, but short enough to fit into busy schedules.
Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:
- Join any virtual and in-person events
- Invite peers to meetings
- Network
- Gain full access to all articles and HealthXL reports
- Get personalised recommendations
- Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
- Full access to community insights and meeting takeaway reports
HealthXL Masterclasses
HealthXL community events give unparalleled access to digital health leaders from around the world.
Our virtual Masterclasses are 60-minute sessions where a recognised expert in their field provides an in-depth learning experience to a small audience of 8-12 members.
HealthXL Masterclasses give you a chance to join a small group of peers and ask questions of recognised experts in a private, convenient setting.
Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:
- Join any virtual and in-person events
- Invite peers to meetings
- Network
- Gain full access to all articles and HealthXL reports
- Get personalised recommendations
- Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
- Full access to community insights and meeting takeaway reports
HealthXL Webinars
HealthXL community events give unparalleled access to digital health experts from around the world.
Our webinars bring together panels of 3-4 global leaders from the HealthXL community to discuss core trends in digital health.
Gain insights on the latest topics in digital health and ask questions of the expert panel via chat. Webinars run for 60 minutes and recordings are shared with all attendees afterwards.
Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:
- Join any virtual and in-person events
- Invite peers to meetings
- Network
- Gain full access to all articles and HealthXL reports
- Get personalised recommendations
- Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
- Full access to community insights and meeting takeaway reports
Join from anywhere
No need for a high end laptop to display fancy 3D personas or interactive conference rooms: All you need is a working camera and an internet-ready device to join.
The world of Digital Health in one Hub
Be ready for the future of Digital Health and join a community of passionate leaders, innovators and gamechangers.
As a HealthXL member, you get access to a wealth of information, resources and connections. From daily curated news by our in-house expert team to industry reports each retailing at €2000 - you have the world of Digital Health right at your fingertips.
Our community is growing fast. Don’t miss out on your opportunity to lead the future.
News
Your Digital Health Corner
All Posts.png)
September 2023 Global Gathering Event Recap Tech in Clinical Trials: It will work!
Read More
Tess’ Top Takes from this Month’s Meetings in Digital Health: August 2023
Read More
This September, our spotlight series is all about medical affairs’ role in digital health!
Read More
Combo DTx-drug: Pharma Opportunities
Combo DTx-drug: Pharma Opportunities
Combo DTx-drug: Pharma Opportunities
DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?
This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss:
- How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?
- When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?
- Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs?
- What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos?
- What does the promotion of these combos look like?
Join this group of peers and get a feel of what it's like to belong to a community of digital health gamechangers.
All meetings are limited to 10 people to allow for honest discussions, so apply fast or become a HealthXL member and get priority access to all meetings, latest industry reports and and much more.
Frequently asked questions:
What are HealthXL Virtual Meetings?
HealthXL Virtual Meetings are private group meetings limited to 10 people across different demographic and stakeholder groups. For 75 minutes, you take a deep dive into your chosen topic and explore it from different angles. Virtual Meetings are not webinars: There is no audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And through our Community Hub, you stay up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.
How can I connect with other digital health leaders?
HealthXL brings together gamechangers of digital health to support honest discussions in small, private groups. In our Community Hub, for which you can register for free, you can follow a wide range of communities across telehealth, digital therapeutics, patient engagement and more. As a full HealthXL member, you also get access to curated news, the latest insights and an expert network to connect with. Join exclusive virtual meetings to exchange strategies, viewpoints and learnings with members from like-minded yet diverse stakeholder groups.
What are the benefits of being a HealthXL community member?
As member of HealthXL, you join a community of digital health thought leaders, innovators and game changers around the world. With your membership, you get access to hundreds of insights, reports and resources. You can browse a database with over 90k healthcare organizations and view their active strategic partnerships, commercial relationships, latest funding rounds and research. Through our in-house curated digital health newsfeed, you stay informed on the most impactful news and you can regularly meet with members to share learnings, discuss the latest developments and connect with peers of different demographical stakeholder groups. Contact us today to find out about pricing options.
Through focus groups, we bring together 6-10 thought leaders and industry stakeholders in a series of virtual meetings to collaborate around a defined topic. Each meeting gives the group the opportunity to examine, analyze and collaborate with one another around a digital health topic as well as produce a shareable result.
